Ultra-early versus early adjunctive vasopressin initiation after norepinephrine escalation in septic shock: a target trial emulation.

Summary

In 3,810 eligible adults with septic shock from MIMIC-IV and eICU-CRD, ultra-early vasopressin initiation within 0–3 hours after norepinephrine escalation was associated with lower weighted 28-day mortality than initiation after 3–6 hours. The ultra-early strategy was also associated with longer restricted mean survival, less renal replacement therapy, and less continuous renal replacement therapy, although acute kidney injury incidence was not reduced.

Key Findings

• Among 3,810 eligible patients, weighted 28-day mortality was 48.1% with ultra-early initiation and 53.0% with early initiation, with a risk difference of −5.0 percentage points.
• Ultra-early vasopressin was associated with a hazard ratio of 0.82 for 28-day mortality and a restricted mean survival time difference of 1.58 days.
• Ultra-early initiation was associated with lower renal replacement therapy and continuous renal replacement therapy, but not lower acute kidney injury.

Clinical Implications

For adults with septic shock requiring norepinephrine at 0.25 μg/kg/min or higher, clinicians may consider initiating adjunctive vasopressin promptly rather than waiting several additional hours. Because the study was observational, the findings should not by themselves mandate a guideline change or replace individualized assessment of perfusion, ischemia risk, and vasopressor response.

Limitations

• The study was based on retrospective electronic health record data and remains vulnerable to residual confounding and treatment-selection bias.
• The cloned strategy-adherent groups were substantially smaller than the initial eligible population, and the findings require prospective validation.

Future Directions

A pragmatic multicenter randomized trial should compare vasopressin initiation immediately after a prespecified norepinephrine threshold with later initiation, incorporating ischemic complications, renal outcomes, lactate clearance, and patient-centered survival endpoints. Future analyses should also examine effect modification by infection source, baseline cardiac function, and severity of shock.